Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Germ Cell Tumors
Interventions
DRUG

Paclitaxel

DRUG

Ifosfamide

DRUG

Cisplatin

DRUG

Mesna

DRUG

Bleomycin

DRUG

Etoposide

Trial Locations (13)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

15213

University of Pittsburgh Medical Center, Pittsburgh

27514

University of North Carolina, Chapel Hill

55905

Mayo Clinic, Rochester

90033

University of Southern California, Los Angeles

94305-5408

Stanford University Medical Center, Stanford

Unknown

University of Chicago, Chicago

Memorial Sloan Kettering Cancer Center, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen (Follow-up Only), Montvale

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Southern California

OTHER

collaborator

Mayo Clinic

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

University of North Carolina

OTHER

collaborator

University of Chicago

OTHER

collaborator

Stanford University

OTHER

collaborator

University of Texas Southwestern Medical Center

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER